Medical and pharmaceutical products account for 65% of export growth
Ireland’s exports soared by more than €6.2 billion in September, representing a 28 percent increase to €28.5 billion, according to the latest figures from the Central Statistics Office.
The dramatic growth was overwhelmingly driven by the medical and pharmaceutical sector, which accounted for more than 65 percent of total exports. Products worth €18.7 billion were shipped abroad, marking an increase of €7.9 billion or 73.6 percent compared to the previous year.
US Market Dominance
Exports to the United States more than doubled in September, surging by 126 percent to €16.3 billion—an increase of €7.2 billion. Chemicals and related products, including medical and pharmaceutical goods, comprised over 90 percent of exports to the American market.
The substantial growth in US-bound exports underscores Ireland’s position as a major pharmaceutical manufacturing hub and the strategic importance of transatlantic trade to the Irish economy.
Imports Rise Modestly
While exports surged, imports also increased in September, though at a more modest pace. Goods worth €11.1 billion entered the country, representing a 4 percent increase of €399.2 million compared to September of the previous year.
Nine-Month Performance
Looking at the first nine months of the year, both exports and imports showed strong growth compared to the same period in 2024. Exports rose by 28 percent to €212.2 billion, while imports increased by 5.5 percent to €104.8 billion.
The figures highlight Ireland’s substantial trade surplus and the continued strength of its export-oriented economy.
Expert Caution on Trade Risks
Robert Purdue, senior portfolio manager at global financial services firm Amundi Ireland, offered a measured assessment of the data. While acknowledging that strong export performance despite US tariff concerns was encouraging, he warned of potential vulnerabilities.
“The majority of Ireland’s exports are pharmaceuticals,” Purdue noted. “This stability could be disrupted if the US imposes further punitive measures in this sector.”
He advised businesses to exercise caution in the current trade environment, as Ireland’s heavy concentration in pharmaceutical exports leaves the economy exposed to sector-specific risks.
Strategic Implications
The figures underscore both the strength and concentration risk of Ireland’s export economy. While the pharmaceutical sector has delivered exceptional growth, the heavy dependence on a single industry and single market creates potential vulnerabilities.
Trade policy changes in the United States, regulatory shifts, or global pharmaceutical market dynamics could have outsized impacts on Ireland’s economic performance given the sector’s dominance in the export mix.
The data will be closely watched by policymakers as they assess Ireland’s economic resilience and consider strategies for export diversification while maintaining the country’s competitive advantages in life sciences and pharmaceutical manufacturing.